CO6331335A2 - Nuevos compuestos antagonistas de los receptores b1 de bradiquinina - Google Patents

Nuevos compuestos antagonistas de los receptores b1 de bradiquinina

Info

Publication number
CO6331335A2
CO6331335A2 CO10016009A CO10016009A CO6331335A2 CO 6331335 A2 CO6331335 A2 CO 6331335A2 CO 10016009 A CO10016009 A CO 10016009A CO 10016009 A CO10016009 A CO 10016009A CO 6331335 A2 CO6331335 A2 CO 6331335A2
Authority
CO
Colombia
Prior art keywords
bradiquinine
receptors
antagonist compounds
new antagonist
compounds
Prior art date
Application number
CO10016009A
Other languages
English (en)
Inventor
Norbert Hauel
Angelo Ceci
Rainer Walter
Annette Schuler-Metz
Ingo Konetzki
Iris Kauffmann-Hefner
Henri Doods
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2007/058408 external-priority patent/WO2008022945A1/de
Priority claimed from PCT/EP2008/052157 external-priority patent/WO2009021758A1/de
Priority claimed from EP08102043A external-priority patent/EP2025673A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO6331335A2 publication Critical patent/CO6331335A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Objeto de la presente invención son compuestos de la fórmula general (I)en la que A, B, D, Y, R1, R2, R3, R4 y R5 se definen como se mencionaron en la descripción, sus enantiómeros, sus diastereómeros, sus mezclas y sus sales, en especial sus sales fisiológicamente tolerables con ácidos o bases orgánicos o inorgánicos, que presentan valiosas propiedades, su preparación, los medicamentos que contienen los compuestos farmacológicamente eficaces, su preparación y su uso.
CO10016009A 2007-08-14 2010-02-12 Nuevos compuestos antagonistas de los receptores b1 de bradiquinina CO6331335A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2007/058408 WO2008022945A1 (de) 2006-08-19 2007-08-14 Arylsulfonamide mit analgetischer wirkung
PCT/EP2008/052157 WO2009021758A1 (de) 2007-08-14 2008-02-21 Arylsulfonamide mit analgetischer wirkung
EP08102043A EP2025673A1 (de) 2007-08-14 2008-02-26 Arylsulfonamide mit analgetischer Wirkung

Publications (1)

Publication Number Publication Date
CO6331335A2 true CO6331335A2 (es) 2011-10-20

Family

ID=40589564

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10016009A CO6331335A2 (es) 2007-08-14 2010-02-12 Nuevos compuestos antagonistas de los receptores b1 de bradiquinina

Country Status (21)

Country Link
US (1) US8394805B2 (es)
EP (1) EP2188269B1 (es)
JP (1) JP5250627B2 (es)
KR (1) KR20100055469A (es)
CN (1) CN101821245B (es)
AR (1) AR068341A1 (es)
AU (2) AU2008288431A1 (es)
BR (1) BRPI0815181A2 (es)
CA (1) CA2696261A1 (es)
CO (1) CO6331335A2 (es)
EA (1) EA201000296A1 (es)
EC (1) ECSP109978A (es)
MA (1) MA31613B1 (es)
MX (1) MX2010001664A (es)
NZ (1) NZ583815A (es)
PE (1) PE20090593A1 (es)
TN (1) TN2010000072A1 (es)
TW (1) TW200911744A (es)
UY (1) UY31287A1 (es)
WO (1) WO2009021944A1 (es)
ZA (1) ZA201008350B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006039003A1 (de) * 2006-08-19 2008-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Verbindungen
WO2010017850A1 (de) * 2008-08-12 2010-02-18 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von cycloalkyl-substituierten piperazinverbindungen
EP2025675A1 (de) 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamide mit analgetischer Wirkung
AU2008288431A1 (en) 2007-08-14 2009-02-19 Boehringer Ingelheim International Gmbh New compounds
JP2011512329A (ja) * 2008-02-06 2011-04-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有効な鎮痛剤としてのアリールスルホンアミド
US8207335B2 (en) * 2009-02-13 2012-06-26 Boehringer Ingelheim International Gmbh Process for making certain compounds having B1 antagonistic activity
US20130289049A1 (en) * 2010-08-05 2013-10-31 Boehringer Ingelheim International Gmbh Acid addition salts of the 2-[2-[[(4-methoxy-2,6-dimethylphenyl)sulfonyl]-(methyl)amino]ethoxy]-n-methyl-n-[3-(4-methylpiperazin-1-yl)cyclohexyl] acetamide and the use thereof as bradykinin b1 receptorantagonists
WO2012022796A2 (de) 2010-08-20 2012-02-23 Boehringer Ingelheim International Gmbh Neue kombinationen
BR112013005193A2 (pt) 2010-09-03 2016-05-03 Gruenenthal Gmbh derivados substituídos de tetra-hidropirrolopirazina

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
EP2014285B1 (en) 1999-11-26 2010-05-05 Shionogi&Co., Ltd. NPYY5 antagonists
FR2819254B1 (fr) 2001-01-08 2003-04-18 Fournier Lab Sa Nouveaux composes de la n-(phenylsulfonyl) glycine, leur procede de preparation et leur utilisation pour obtenir des compostions pharmaceutiques
FR2840897B1 (fr) * 2002-06-14 2004-09-10 Fournier Lab Sa Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
AU2003299757A1 (en) 2002-12-19 2004-07-14 Elan Pharmaceuticals Inc. Substituted n-phenyl sulfonamide bradykinin antagonists
CN1756551A (zh) * 2003-01-31 2006-04-05 普雷迪克医药品控股公司 新型芳基哌嗪基化合物
MXPA05010288A (es) 2003-03-25 2005-11-17 Fournier Lab Sa Derivados de bencenosulfonamida, metodo para su produccion y uso de los mismos para el tratamiento del dolor.
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
EP1799637A1 (en) 2004-09-23 2007-06-27 Amgen, Inc Substituted sulfonamidopropionamides and methods of use
WO2006035967A1 (en) 2004-09-30 2006-04-06 Taisho Pharmaceutical Co., Ltd. Pyridine derivatives and their use as medicaments for treating diseases related to mch receptor
DE102005013967A1 (de) 2004-11-05 2006-10-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20060217362A1 (en) 2004-12-29 2006-09-28 Tung Jay S Novel compounds useful for bradykinin B1 receptor antagonism
JP5603770B2 (ja) 2007-05-31 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体拮抗薬およびその使用
DE102007034620A1 (de) 2007-07-25 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue B1-Antagonisten
AU2008288431A1 (en) 2007-08-14 2009-02-19 Boehringer Ingelheim International Gmbh New compounds
DE502008002979D1 (de) 2007-08-14 2011-05-05 Boehringer Ingelheim Int Arylsulfonamide mit analgetischer wirkung
DE102007046887A1 (de) 2007-09-28 2009-04-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von (1R,5S)-Anhydroecgoninestersalzen

Also Published As

Publication number Publication date
AU2009281472A1 (en) 2010-02-18
US8394805B2 (en) 2013-03-12
KR20100055469A (ko) 2010-05-26
AR068341A1 (es) 2009-11-11
US20110098282A1 (en) 2011-04-28
AU2008288431A1 (en) 2009-02-19
PE20090593A1 (es) 2009-06-03
CN101821245B (zh) 2012-10-10
BRPI0815181A2 (pt) 2015-03-31
CA2696261A1 (en) 2009-02-19
NZ583815A (en) 2012-03-30
TW200911744A (en) 2009-03-16
WO2009021944A1 (de) 2009-02-19
TN2010000072A1 (en) 2011-09-26
JP2010535839A (ja) 2010-11-25
ECSP109978A (es) 2010-03-31
JP5250627B2 (ja) 2013-07-31
ZA201008350B (en) 2011-08-31
EP2188269B1 (de) 2014-05-07
EP2188269A1 (de) 2010-05-26
MA31613B1 (fr) 2010-08-02
UY31287A1 (es) 2009-04-30
CN101821245A (zh) 2010-09-01
MX2010001664A (es) 2010-03-10
EA201000296A1 (ru) 2010-08-30

Similar Documents

Publication Publication Date Title
CO6331335A2 (es) Nuevos compuestos antagonistas de los receptores b1 de bradiquinina
ECSP12012161A (es) Compuestos en calidad de antagonistas de Bradiquinina-b1
UY30979A1 (es) Pirrolidinamidas sustituidas, su preparacion y su uso como medicamentos
UY29437A1 (es) Nuevos antagonistas de cgrp
ECSP088824A (es) Prolinamidas sustituidas, su preparación y su uso como medicamentos
UY28859A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
ECSP10010722A (es) Compuestos orgánicos
UY28848A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparación, y su empleo como medicamentos
UY29071A1 (es) Aminas policíclicas sustituidas con arilo, procedimientos para su preparación y su uso como medicamentos.
UY31524A1 (es) Nuevos compuestos 010
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
UY27722A1 (es) Nuevas piperidinas sustituidas, medicamentos que contienen estos compuestos y procedimientos para su preparación.
ECSP10010105A (es) Antagonistas de cgrp
ECSP078058A (es) Nuevas glicinamidas sustituidas, su preparación y su uso como medicamentos
CO6321254A2 (es) Pirimidin -5-carboxamidas sustituidas 281
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
UY31712A1 (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmacéuticas que los contienen
UY29749A1 (es) Antagonistas de cgrp seleccionados, procedimientos para su preparación, así como su uso como medicamentos
GT200900026A (es) Derivados de 5,6 -bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
ECSP13012495A (es) Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina
UY31286A1 (es) Antagonistas de receptores de bradiquinina b1. proceso de preparación y aplicaciones.
HN2011000404A (es) Derivados de enfumafungina y composicion comprendiendo los mismos
UY29804A1 (es) Quinolinas de alquilnitrilo
UY31643A1 (es) Imidazolidina-2,4-dionas arilcalcogenoarilalquil-sustituidas, procedimiento para su preparación, medicamentos que comprenden estos compuestos y uso de las mismas
UY31642A1 (es) Imidazolidina-2,4.dionas sustituidas con arilo, procesos para su preparación, medicamentos que comprenden estos compuestos y uso de los mismos.

Legal Events

Date Code Title Description
FG Application granted